Ascletis Pharma (ASCLF) News Today → Proof that the Musk/Bezos rivalry is about to hit a new level (From InvestorPlace) (Ad) Free ASCLF Stock Alerts $0.20 0.00 (0.00%) (As of 05/9/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAscletis Announces Strategic Decisions on FXR agonist ASC42prnewswire.com - April 3 at 5:10 AMAscletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meetingprnewswire.com - March 10 at 8:10 PMWeek In Review: Arrivent BioPharma Raises $175M In IPO For In-Licensings From Chinaseekingalpha.com - January 28 at 11:23 AMAscletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acnefinance.yahoo.com - January 24 at 7:48 AMGannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASHfinance.yahoo.com - January 23 at 1:33 AMGannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitisfinance.yahoo.com - January 2 at 9:48 AMAscletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acnefinance.yahoo.com - December 5 at 7:52 AMAscletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHBfinance.yahoo.com - November 12 at 7:56 PMDr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023finance.yahoo.com - November 8 at 9:16 PMGannex Published Phase I Data of ASC42, a Novel Farnesoid X Receptor Agonist on the Journal Drugs in R&Dfinance.yahoo.com - November 6 at 12:30 AMAscletis Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Curefinance.yahoo.com - September 28 at 8:48 PMAscletis enrols all patients in trial of glioblastoma therapymsn.com - September 26 at 8:38 AMAscletis Announces Completion of Enrollment of 120 Patients in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastomafinance.yahoo.com - September 26 at 12:28 AMClinical Results of ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection Presented at the 12th IAS Conference on HIV Scienceprnewswire.com - July 24 at 10:01 PMAscletis Announces Poster Presentation of Phase II Study of ASC42 FXR Agonist for Functional Cure of Chronic Hepatitis B at EASL CONGRESS 2023finance.yahoo.com - June 26 at 12:06 AMAscletis Pharma: China Approves To Conduct Phase IIa Clinical Trial For ASC10 To Treat RSV Infectionmarkets.businessinsider.com - May 8 at 8:05 AMAscletis Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infectionfinance.yahoo.com - May 8 at 8:05 AMAscletis Announces ASC40, a First-in-Class, Once-Daily Oral FASN Inhibitor, Achieved Endpoints in Phase II Clinical Trial for Acnefinance.yahoo.com - May 2 at 7:00 AMAscletis (1672.HK) Included in the Hang Seng Hong Kong-Listed Biotech Indexfinance.yahoo.com - February 27 at 6:03 AMAscletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infectionfinance.yahoo.com - January 31 at 7:59 AMAscletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China NMPAfinance.yahoo.com - January 26 at 12:15 PMSupply enters ritonavir tablets supply agreement with Simceremsn.com - January 17 at 8:18 AMAscletis Announces Entering into a Supply Agreement of Ritonavir Tablets with Simcerefinance.yahoo.com - January 16 at 8:21 PMAscletis Announces Dosing of 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19finance.yahoo.com - January 15 at 10:43 PMViking Therapeutics sues Ascletis Pharma for stealing trade secretsmsn.com - January 3 at 8:37 AMAscletis' NASH Drug ASC41(THRβ) Phase II Enrollment is Progressing as Plannedfinance.yahoo.com - December 20 at 11:14 PMAscletis Announces Notice of Issuance of the U.S. Patent for Oral Viral Polymerase Inhibitor ASC10 and Its Derivativesfinance.yahoo.com - December 19 at 9:25 AMAscletis Announces Positive Early-Stage Results Of Oral RdRp Inhibitor ASC10 For COVID-19markets.businessinsider.com - December 12 at 4:03 PMAscletis Announces Positive Phase I Clinical Results of Oral RdRp Inhibitor ASC10 for COVID-19finance.yahoo.com - December 12 at 4:03 PMAscletis Pharma Shares Gain After Covid-19 Drug Approved for Clinical Trialmarketwatch.com - December 7 at 10:38 PMAscletis Pharma Announces IND Approval For ASC11 In China - Quick Factsmarkets.businessinsider.com - December 7 at 7:27 AMAscletis gets Chinese drug regulator nod to start trial of oral COVID therapyseekingalpha.com - December 7 at 7:27 AMAscletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for Acnefinance.yahoo.com - November 30 at 11:46 AMAscletis Pharma : FDA Approves IND Of Oral 3CLpro Inhibitor ASC11 For COVID-19markets.businessinsider.com - November 23 at 8:53 AMAscletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDAfinance.yahoo.com - November 23 at 8:53 AMAscletis Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPAfinance.yahoo.com - November 16 at 8:44 PMAscletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19finance.yahoo.com - November 1 at 9:31 PMAscletis Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indicationfinance.yahoo.com - October 26 at 10:05 AMWeek In Review: AIM Vaccine Stages $20 Million IPO On Hong Kong Exchangeseekingalpha.com - October 10 at 12:16 AMAscletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19finance.yahoo.com - October 10 at 12:16 AMAscletis Announces Dosing of the First Patient in Phase II Clinical Trial of THRβ Agonist ASC41 for 52-Week Treatment of Liver Biopsy-Proven NASHfinance.yahoo.com - October 4 at 8:55 PMAscletis Pharma Inc (1672)investing.com - September 29 at 9:19 PMShanghai Public Health Clinical Center Completed Patient Enrollment in Clinical Study of PD-L1 Antibody ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infectionfinance.yahoo.com - September 15 at 10:32 AMAscletis Pharma : China Approves IND Of Oral RdRp Inhibitor ASC10 For COVID-19nasdaq.com - August 21 at 11:19 PMGannex Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitisfinance.yahoo.com - August 16 at 10:30 AMAscletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1 Small Molecule Inhibitor Prodrug ASC61 for Treatment of Advanced Solid Tumorsfinance.yahoo.com - August 7 at 9:24 PMAscletis Announces IND Filing of Oral RdRp Inhibitor ASC10 for COVID-19 Accepted by China NMPAfinance.yahoo.com - August 3 at 8:24 PMAscletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patientsfinance.yahoo.com - August 3 at 10:23 AMCould Covid Drugs Help Cure Financial Ills At Ascletis Pharma?seekingalpha.com - July 13 at 1:49 PMAscletis Pharma Announces U.S. IND Filing Of Oral Drug Candidate ASC10 For COVID-19nasdaq.com - July 6 at 1:57 AM Get Ascletis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ASCLF and its competitors with MarketBeat's FREE daily newsletter. Email Address This 1 Biotech Stock has been shocking the markets (Ad)Save the Date: BioStem's 2024 Q1 Call Coming Up! Sign Up for the Live Broadcast here ASCLF Media Mentions By Week ASCLF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ASCLF News Sentiment▼0.000.45▲Average Medical News Sentiment ASCLF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ASCLF Articles This Week▼00▲ASCLF Articles Average Week Get Ascletis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ASCLF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Algernon Pharmaceuticals News Today ALK-Abelló A/S News Today Alpha Tau Medical News Today Arno Therapeutics News Today Artelo Biosciences News Today AVAX Technologies News Today Awakn Life Sciences News Today AXIM Biotechnologies News Today BerGenBio ASA News Today BriaCell Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:ASCLF) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThis 1 Biotech Stock has been shocking the marketsHuge AlertsProof that the Musk/Bezos rivalry is about to hit a new levelInvestorPlaceTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold GroupForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward PressHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascletis Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
